Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

AURORA, Ontario, Oct. 29 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced financial results for the year ended July 31, 2009.

During the 2009 fiscal year, the Company continued to make progress with its development initiatives for its lead drug candidates, L-DOS47 and Topical Interferon Alpha-2b. The following are selected highlights during the 2009 fiscal year and subsequent to year-end.

FISCAL 2009 HIGHLIGHTS

DOS47/L-DOS47

  • A pre-IND meeting with the U.S. Food and Drug Administration ("FDA") was held for L-DOS47 in which the FDA generally agreed with Helix's proposed remaining non-clinical pharmacology and toxicology studies as well as its remaining GMP manufacturing program initiatives prior to IND filing.
  • Helix announced plans to conduct a Phase I/II clinical study of non-small cell lung cancer ("NSCLC") patients in Poland. Helix has been finalizing these plans with key opinion leader clinicians and contract research organizations in Poland. The study is expected to run concurrently with the U.S. Phase I trial in refractory solid tumor patients. The timing of both studies will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.

Topical Interferon Alpha-2b

  • A pre-IND meeting with the FDA was held in which the FDA confirmed the acceptability of a Phase II/III, randomized, vehicle-controlled clinical trial as the next step in the compound's clinical development plan for patients with cervical dysplasia. The FDA also confirmed Helix's expectation that an additional well-controlled, Phase III confirmatory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose.
  • The Phase II pharmacokinetic
    '/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is ... Inc. ("Vitae" or the "Company") (NASDAQ: VTAE ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... and certain of its officers and/or directors have violated ... of 1934.  On February 27, 2015, ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... 27, 2015 Report Details   ... you trends, R&D progress, and predicted revenues ,Where is ... are the commercial prospects for this market and related ... and other trends to 2025, discussing data, opportunities and ... assess regenerative medicine : cell-based therapies that aim ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 28 Preliminary results of a pre-specified subgroup ... that the investigational triple combination therapy of olmesartan medoxomil ... statistically significant greater Least Squares (LS) mean reduction in ... Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or ...
... Mass. , June 28 Tolerx, Inc., ... diseases and cancer by modulating T cell activity, today ... trial to further evaluate otelixizumab in autoimmune new-onset type ... called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4
(Date:2/27/2015)... 27, 2015 Clinovo, a leading provider ... Electronic Data Capture (EDC) at the CALBIO2015 ... 2nd and March 3rd at Booth # 141. ... DIY CRF and edit-check builder allowing Clinical Trials Managers ... of days, without any programming experience. Clinovo’s new pricing ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 In ... to the community by providing free dental care from ... has partnered with Dentistry from the Heart, and ... 11, 2015. The first 50 patients who are in ... they can’t afford, will have access to high­quality service ...
(Date:2/27/2015)... Mequon, Wisconsin (PRWEB) February 27, 2015 ... facial plastic surgeons , is pleased to announce the ... location now open in Delafield. Quintessa has begun seeing ... Campbell, the new Delafield location will offer a variety ... patients, including: Botox, filler injectables, micro laser peels, chemical ...
(Date:2/27/2015)... Winter is here, and with it comes harsh snow and ... ice can be harmful on a dog’s paws. Commonly used ... is ready to help pet owners know what to look ... time. , Ice melts can lead to several health hazards ... ice melt products may cause depression, loss of appetite, disorientation, ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized as ... hospital. In order to receive the award, Florida Hospital ... Get With The Guidelines - Stroke Quality Achievement indicators ... 75-percent or higher compliance with six of 10 Get ... reporting initiatives to measure quality of care. ...
Breaking Medicine News(10 mins):Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2
... Oct. 30 As clashes between,rebels and government ... of Congo, International Medical Corps (IMC) continues,delivering emergency ... maintain the safety of its staff., Tens ... violence north of,Goma. International Medical Corps staff began ...
... ... care, PLEASANTON, ... & Drug Administration (FDA) has approved,the COBAS(R) AmpliPrep / COBAS(R) TaqMan(R) HCV ... PCR technology to,quantify the amount of Hepatitis C RNA in a patient,s ...
... C630 Convertible Car Seat earns top honors for a four-star ... rating for both rear and front ... Curve,Brands, Inc., a wholly owned subsidiary of RC2 Corporation (Nasdaq: ... National,Highway Traffic Safety Administration (NHTSA), giving The First Years True,Fit ...
... today that it plans to report third quarter 2008 financial results before ... ... Calif. (Business Wire EON) October 30, 2008 -- The company also ... Healthcare Conference in New York City on November 3, 2008 at 11:20 ...
... Investigators combing the genome in the hope of ... be looking in the wrong place, new research at ... diabetes, also known as type-1 diabetes, is an autoimmune ... ,insulin-producing cells in a person,s pancreas. , What triggers ...
... Draws from Kaiser/Harvard Survey of Registered Voters in,September, As ... Exit Polls, MENLO PARK, Calif., Oct. 30 ... from Harvard School of,Public Health and the Kaiser Family ... of Medicine (NEJM), find that seven in ten,registered voters ...
Cached Medicine News:Health News:International Medical Corps Continues Delivering Emergency Relief Amid Violence in Democratic Republic of Congo 2Health News:Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform 2Health News:Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform 3Health News:The First Years True Fit C630 Convertible Car Seat Recieves Highest Given Rating From the National Highway Traffic Safety Administration 2Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 3Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 4Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 2Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 3Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 4
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room....
Medicine Products: